Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients
Molecular tumor profiling of ctDNA identifies therapeutically relevant mutations at a comparable rate to tumor tissue-based NGS and might therefore serve as an alternative or complementary test for the detection of actionable variants in plasma.
Authors
- Anthonie J. van der Wekken (ORCID: https://orcid.org/0000-0001-7175-0026)
- Hanneke Kievit
- Léon C.L.T. van Kempen (ORCID: https://orcid.org/0000-0003-0646-0705)
- Ed M. D. Schuuring (ORCID: https://orcid.org/0000-0003-3655-143X)
- Pim Rozendal (ORCID: https://orcid.org/0000-0002-0741-2249)
- Vincent D. de Jager (ORCID: https://orcid.org/0009-0009-3539-8809)
- Naomi Rifaela
- Paul van der Leest (ORCID: https://orcid.org/0000-0001-8527-4956)
- T. Jeroen N. Hiltermann (ORCID: https://orcid.org/0000-0002-0665-2160)
- Grigory Sidorenkov (ORCID: https://orcid.org/0000-0002-1926-8862)
Institutions
- University Medical Center Groningen (NL)
- University of Antwerp (BE)
- University of Groningen (NL)
- The Netherlands Cancer Institute (NL)
- Antwerp University Hospital (BE)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-05-28
- DOI
- https://doi.org/10.1038/s43856-025-00921-8
- Citations
- 13
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 12.17
Funders
- Universitair Medisch Centrum Groningen